Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia - Vigipallia

0 avis

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Archive ouverte

Sharman, Jeff | Egyed, Miklos | Jurczak, Wojciech | Skarbnik, Alan | Pagel, John | Flinn, Ian | Kamdar, Manali | Munir, Talha | Walewska, Renata | Corbett, Gillian | Fogliatto, Laura Maria | Herishanu, Yair | Banerji, Versha | Coutre, Steven | Follows, George | Walker, Patricia | Karlsson, Karin | Ghia, Paolo | Janssens, Ann | Cymbalista, Florence | Woyach, Jennifer | Ferrant, Emmanuelle | Wierda, William | Munugalavadla, Veerendra | Yu, Ting | Wang, Min Hui | Byrd, John

Edité par CCSD ; Springer Nature -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Archive ouverte | Sharman, Jeff | CCSD

International audience

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

Archive ouverte | Cohen, Jonathon | CCSD

International audience

ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results

Archive ouverte | Cohen, Jonathon | CCSD

International audience

Chargement des enrichissements...